For Strategic Partners & Investors
One Focus.
One Market.
One Proven System.
The essence of strategy is choosing what not to do. We have chosen Japan — and within Japan, we have chosen one niche, one city, one entry point. This document explains why.
Strategy
The Porter Principle
Michael Porter's core insight: sustainable competitive advantage comes not from doing everything, but from doing one thing better than anyone else — and building a system around it. FasciaClinics Japan is built on this principle. We do not compete with Japanese wellness. We occupy a space that does not yet exist.
"The essence of strategy is choosing what not to do." — Michael Porter
01 — Trust
Why Japan Trusts This
Before numbers, there is trust. In Japan, trust is built through track record, through networks, and through alignment with existing values — not through marketing claims.
16 Years of R&D
FasciaClinics is not a startup. It is a 16-year research and clinical programme that has delivered 100,000+ treatments across Sweden and Europe.
Swedish Scientific Credibility
Uppsala University, peer-reviewed fascia research, and a patented technology with the German Design Award 2020. Science-backed, not trend-driven.
Japanese Network
Atsuo Shiga — former Sumitomo executive, Kobe University MBA — has built a coalition that includes Atleta (15,000 members), Diossa FC, Nakai-san (Finance Ministry connections), and the Izumo municipal network.
Aligned with Government Policy
Female athlete empowerment, preventive healthcare, and wellness tourism are all active Japanese government priorities. This initiative aligns with — not against — existing policy direction.
02 — Proof
The Proof
Numbers from the Swedish market, translated to Japanese context.
100,000+
Treatments delivered
12–18 months
Average ROI timeline
¥220,000+
Net monthly revenue (conservative)
€35K–€52K
Franchisee initial capital
16
Years of clinical R&D
1,356
Google Reviews (avg. 4.8★)
Japan Revenue Forecast
Based on the FasciaClinics International investor model. Japan is projected to contribute 33% of total group revenue by 2029.
| Year | Japan Revenue (EUR) | Japan Revenue (JPY) | % of Group |
|---|---|---|---|
| 2026 | €0.2M | ¥32M | 6% |
| 2027 | €1.7M | ¥272M | 23% |
| 2028 | €3.9M | ¥624M | 30% |
| 2029 | €5.7M | ¥912M | 33% |
Management estimates. Not guarantees. Based on conservative franchise rollout assumptions.
03 — Process
The Process
We do not ask for a leap of faith. We ask for one step at a time — each step proven before the next begins.
Step 1 — Proof (2026)
One Clinic in a Box. One city (Izumo). One September retreat (30–40 guests). One set of measurable outcomes. This is the test bed.
Step 2 — Validate (2026–2027)
Expand to 3–5 locations in Shimane prefecture. Train Japanese therapists. Establish the subscription model. Demonstrate repeatability.
Step 3 — Scale (2027–2030)
National rollout via Atleta's 15,000-member network. Female athlete programme across Nadeshiko League (24 clubs) → WE League (12 clubs) → JFA (1,320 teams). ¥13 trillion rehabilitation market as the third track.
04 — Risk & Answers
The Questions You Are Thinking
In Japan, the most important questions are often not asked directly. We answer them here.
What if the pilot fails?
The pilot is designed to generate learning, not just revenue. If September 2026 does not meet targets, we have 12 months of data to refine the model before any national commitment is made. The structure protects all parties.
What is the commitment period?
The initial pilot requires no long-term commitment from Japanese partners. The LLC structure allows for a 90-day evaluation period. National expansion is a separate decision, made only after pilot results are reviewed.
Why not a Japanese company?
Because the technology, the methodology, and the 16-year clinical database are Swedish. What we are building together is a Japanese delivery system for a proven Swedish science. The value is in the combination — not in either alone.
What happens to the machine certification?
Atlasbalans cannot be sold in Japan without Japanese certification (~¥3M). During the pilot phase, machines are owned and operated by FasciaClinics Japan LLC — no certification required for in-house use. The certification process begins in parallel with the pilot.
05 — Co-Creation
What We Build Together
This is not a vendor relationship. It is a co-creation.
What Japan brings
- Cultural depth — omotenashi as a delivery system
- Network access — Atleta, Diossa, Nakai-san, municipal government
- Market knowledge — pricing, regulation, consumer behaviour
- Legitimacy — alignment with government wellness and female empowerment initiatives
What FasciaClinics brings
- 16 years of clinical R&D and 100,000+ treatments
- Patented Atlasbalans technology (German Design Award 2020)
- Complete franchise system — training, CRM, protocols, branding
- Fascia Age — measurable biological outcome that no competitor can offer
06 — Next Step
Next Step
If this document raises questions, we welcome them. The next step is a direct conversation — not a commitment.
[email protected]Alexandra Reenstierna — Japan Operations Lead